Cryptococcus neoformans is the leading cause of fungal meningoencephalitis and one of the major causes of death in immunocompromised individuals; this AIDS-defining illness has a reported fatality rate of up to 20% in high-income countries such as Australia, and as high as 65% in developing . Development of resistance to these drugs is an ever-present threat given the pathogen undergoes microevolution while infecting the host, with evidence that this contributes to the high rate of relapse. It is therefore essential that we develop additional classes of antifungal drugs, particularly ones that are more effective than those currently available. But due to the shared eukaryotic physiology of fungi and humans, gross differences that can be exploited as drug targets such as those targeted by current antifungals are limited.
. The current treatment regime recommended by the World Health Organization is induction therapy with flucytosine and amphotericin B, followed by maintenance and consolidation therapy of fluconazole 3 . Development of resistance to these drugs is an ever-present threat given the pathogen undergoes microevolution while infecting the host, with evidence that this contributes to the high rate of relapse. It is therefore essential that we develop additional classes of antifungal drugs, particularly ones that are more effective than those currently available. But due to the shared eukaryotic physiology of fungi and humans, gross differences that can be exploited as drug targets such as those targeted by current antifungals are limited.
Rather than focus on large differences between fungal and human physiology, one approach that can be taken in the pursuit of new antifungal targets is a rational drug design approach to exploit subtle differences in otherwise conserved pathways. Rational drug design was pioneered in the purine metabolic pathway 4 , and this is one of the pathways providing exciting new avenues for antifungal development. The purine metabolic pathway is extremely well characterised in humans, and is the target for drugs such as mercaptopurine and mycophenolic acid that compromise cells with an increased demand for nucleotides due to their rapid proliferation 5 .
However, little investigation has been undertaken into purine metabolism as a potential antifungal target. Given its environmental niche of purine-rich pigeon guano, C. neoformans is an ideal candidate in which to study the necessity of purine biosynthesis during infection.
With the aid of a phosphoribosyltransferase, C. neoformans can readily salvage purines from pigeon guano in its environmental niche. However, upon entering the human host, purine availability Under the Microscope MICROBIOLOGY AUSTRALIA * MAY 2015
